The role of dermatological manifestations in the early diagnosis of Fabry disease: a scoping review.
6 affiliations
- 1University Department of Life Science and Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy.
- 2CEDRI, Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy.
- 3Genetic Counseling Unit, Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy.
- 4Rare Skin Diseases Center, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy.
- 5Hospital Management, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
- 6Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
Abstract
Fabry disease (FD) is a rare X-linked lysosomal storage disorder characterized by the progressive accumulation of globotriaosylceramide in multiple organs. Despite the availability of disease-specific therapies, diagnosis is often delayed due to heterogeneous and nonspecific manifestations. This review aimed to synthesize current evidence on dermatological manifestations of FD and their potential contribution to earlier disease recognition. A scoping review was conducted following the Arksey and O'Malley framework and the PRISMA-ScR guidelines. PubMed, Scopus, and Web of Science were searched for relevant studies, and additional records were identified through snowballing of reference lists from retrieved reviews. Thirty-two records were included, comprising data on 2,209 patients, with detailed patient-level information available for 146 individuals. Dermatologists were involved in the diagnostic process in 66% of the included studies, and 69% of these reported a potential contribution of dermatological evaluation to earlier disease recognition. Angiokeratomas (88% of included studies) and hypohidrosis (50% of included studies) were the most frequently reported cutaneous manifestations. Skin biopsy or histopathological examination was reported in 59% of included studies and was the most frequently reported dermatological investigative technique. Among patients with dermatological manifestations and available diagnostic delay information, 66% had a reported diagnostic delay of 1-10 years. These findings suggest that dermatological manifestations may contribute to earlier recognition of FD. However, they should be interpreted cautiously given the descriptive nature of the available evidence, the absence of an appropriate comparator group, and the potential influence of selection and publication bias.
Related
- Neurological Manifestations in Whipple's Disease: A Scoping Review of Clinical Features, Laboratory Findings, and Neuroimaging Characteristics of 111 Cases
- Artificial Intelligence-Guided Extracellular Vesicle Platforms for Diagnosis and Treatment of Chronic Kidney Disease: A Scoping Review and Future Directions
- Standardized Clinical Photography for Improving Dermatological Treatment Adherence (Scoping Review): Evidence Landscape and Research Gaps.
- Machine Learning in the Differential Diagnosis of Bipolar and Borderline Personality Disorders: A Scoping Review
- Delays From Clinical Manifestations to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A National Retrospective Cohort Study
BibTeX
@article{maio2026role,
title = {{The role of dermatological manifestations in the early diagnosis of Fabry disease: a scoping review.}},
author = {Alessandra Maio and Jo Linda Maria Sinagra and Giulia Pascolini and Gerardo Altamura and Giovanni Di Zenzo and Annarita Panebianco},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1899166},
url = {https://europepmc.org/article/MED/42909177},
note = {CC BY},
}
RIS
TY - JOUR
TI - The role of dermatological manifestations in the early diagnosis of Fabry disease: a scoping review.
AU - Alessandra Maio
AU - Jo Linda Maria Sinagra
AU - Giulia Pascolini
AU - Gerardo Altamura
AU - Giovanni Di Zenzo
AU - Annarita Panebianco
PY - 2026
DA - 2026/10/06
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1899166
UR - https://europepmc.org/article/MED/42909177
AB - Fabry disease (FD) is a rare X-linked lysosomal storage disorder characterized by the progressive accumulation of globotriaosylceramide in multiple organs. Despite the availability of disease-specific therapies, diagnosis is often delayed due to heterogeneous and nonspecific manifestations. This review aimed to synthesize current evidence on dermatological manifestations of FD and their potential contribution to earlier disease recognition. A scoping review was conducted following the Arksey and O'Malley framework and the PRISMA-ScR guidelines. PubMed, Scopus, and Web of Science were searched for relevant studies, and additional records were identified through snowballing of reference lists from retrieved reviews. Thirty-two records were included, comprising data on 2,209 patients, with detailed patient-level information available for 146 individuals. Dermatologists were involved in the diagnostic process in 66% of the included studies, and 69% of these reported a potential contribution of dermatological evaluation to earlier disease recognition. Angiokeratomas (88% of included studies) and hypohidrosis (50% of included studies) were the most frequently reported cutaneous manifestations. Skin biopsy or histopathological examination was reported in 59% of included studies and was the most frequently reported dermatological investigative technique. Among patients with dermatological manifestations and available diagnostic delay information, 66% had a reported diagnostic delay of 1-10 years. These findings suggest that dermatological manifestations may contribute to earlier recognition of FD. However, they should be interpreted cautiously given the descriptive nature of the available evidence, the absence of an appropriate comparator group, and the potential influence of selection and publication bias.
SN - 2296-858X
ER -